New Mexico (NM) is the only state with the capacity to fully monitor cervical cancer screening and HPV prevention using a state-wide woman-based informatics system under mandated reporting. We are thus uniquely positioned to address gaps in understanding HPV vaccine effectiveness within a multi-cultural US population suffering many health disparities. Project 3 will accomplish 4 overarching objectives using realworid population-based evaluations in NM. 1) Among NM women <30 years of age, we have characterized the HPV genotype distribution in a population-based sample of 30,000 normal and 15,000 abnormal cytology specimens collected in 2007-2008. We will estimate the 5-year incidence rate for outcomes of all abnormal histopathologic diagnoses (CIN1, CIN2, and CIN3) during a time period when few screening women (<5- 10%) will have been vaccinated.
This aim will provide baseline incidence rates to which subsequent HPV genotype-specific incidence rates among future vaccinated cohorts can be compared. 2) To evaluate the impact of vaccination on the incidence of cervical abnormalities, we will use the NM State-wide Immunization Information System to identify a cohort of young women age 14-18 who received HPV vaccine in 2007-2008 (-25,000 women) and a cohort of the same age who did not receive vaccine (-50,000 women). Using data linkage, we will estimate and compare the 5-year incidence rates of abnormal histologic diagnoses in these two cohorts through 2014. Although many hypothetical changes to cervical screening among HPV vaccinated women have been proposed, reductions in CIN incidence rates must be observed before modifications can be justified. 3) As an eariy measure of population effectiveness, we will characterize HPV genotype-specific changes in cytologic diagnoses (normal, ASC-US, LSIL, and HSIL) and histologic abnormalities (CIN1,2,3) realized through HPV vaccination as it is being implemented. To accomplish this aim, we will compare HPV genotype distributions among these diagnostic categories in women <25 years of age during two time periods, 2007-2008 and 2012-2013. In the later period, a significant proportion of women screening will have been vaccinated. 4) We will characterize population-based screening practices (e.g. Pap and HPV test utilization and intervals between abnormal diagnosis and biopsy or treatment) for NM women across 2007-2014 and reveal any changes potentially related to HPV vaccine uptake. These data are critical to effective integration of HPV vaccination and screening strategies, to understanding current practices vs. guidelines and to measuring any impact of vaccination on screening compliance.

Public Health Relevance

In the background of highly successful US cervical cancer screening, our project conducted in a population suffering many health disparities will characterize real worid HPV vaccine effectiveness decades before any potential impact on cervical cancer incidence may be realized. Current HPV vaccines cover only 4 of more than 15 HPV types causing genital disease and many questions about vaccine safety and impact remain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI084081-05
Application #
8527689
Study Section
Special Emphasis Panel (ZAI1-MMT-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$755,795
Indirect Cost
$246,195
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Joste, Nancy E; Ronnett, Brigitte M; Hunt, William C et al. (2015) Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 24:230-40
Cuzick, Jack; Myers, Orrin; Hunt, William C et al. (2015) Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer 136:2854-63
Starling, Randall; Nodulman, Jessica A; Kong, Alberta S et al. (2014) Beta-test Results for an HPV Information Web site: GoHealthyGirls.org - Increasing HPV Vaccine Uptake in the United States. J Consum Health Internet 18:226-237
Kinney, Walter; Hunt, William C; Dinkelspiel, Helen et al. (2014) Cervical excisional treatment of young women: a population-based study. Gynecol Oncol 132:628-35
Tyler, Mitchell; Tumban, Ebenezer; Dziduszko, Agnieszka et al. (2014) Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine 32:4267-74
Wheeler, Cosette M; Hunt, William C; Cuzick, Jack et al. (2014) The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States. Int J Cancer 135:624-34
Dunne, Eileen F; Markowitz, Lauri E; Taylor, La'shan D et al. (2014) Human papilloma virions in the laboratory. J Clin Virol 61:196-8
Tyler, Mitchell; Tumban, Ebenezer; Chackerian, Bryce (2014) Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines 13:247-55
Cuzick, Jack; Myers, Orrin; Hunt, William C et al. (2014) A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev 23:765-73
Castle, Philip E; Hunt, William C; Langsfeld, Erika et al. (2014) Three-year risk of cervical precancer and cancer after the detection of low-risk human papillomavirus genotypes targeted by a commercial test. Obstet Gynecol 123:49-56

Showing the most recent 10 out of 23 publications